Ontario-based Canntab is developing advanced pharmaceutical-grade formulations of cannabinoids
Ltd () said Sheldon Inwentash had resigned from the board of directors to pursue other opportunities.
"I would like to thank Sheldon for his valuable contributions to the company, and, on behalf of the board, I wish him every success in his future endeavours," said Jeffrey Renwick, Canntab chief executive.
READ: Canntab Therapeutics merging medical cannabis with pharmaceutical expertise
Ontario-based Canntab is developing advanced pharmaceutical-grade formulations of cannabinoids.
It has in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained-release pharmaceutical dosages for therapeutic use.
It recently filed two additional Canadian patent applications, bolstering its intellectual property portfolio. Canntab's portfolio now includes 13 applications in Canada, the US and internationally.
Canntab is the first company to offer medical marijuana in pill form in Canada and possibly the rest of the world.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE